Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome
Rationale Studies in the Fmr1 knockout (KO) mouse, a model of fragile X syndrome (FXS), suggest that excessive signaling through group I metabotropic glutamate receptors (mGluRs), comprised of subtypes mGluR1 and mGluR5, may play a role in the pathogenesis of FXS. Currently, no studies have assessed...
Saved in:
| Published in: | Psychopharmacologia Vol. 219; no. 1; pp. 47 - 58 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Berlin/Heidelberg
Springer-Verlag
01-01-2012
Springer Springer Nature B.V |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Rationale
Studies in the
Fmr1
knockout (KO) mouse, a model of fragile X syndrome (FXS), suggest that excessive signaling through group I metabotropic glutamate receptors (mGluRs), comprised of subtypes mGluR1 and mGluR5, may play a role in the pathogenesis of FXS. Currently, no studies have assessed the effect of mGluR1 modulation on
Fmr1
KO behavior, and there has not been an extensive behavioral analysis of mGluR5 manipulation in
Fmr1
KO mice.
Objectives
The goals for this study were to determine if pharmacologic blockade of mGluR1 may affect
Fmr1
KO behavior as well as to expand on the current literature regarding pharmacologic blockade of mGluR5 on
Fmr1
KO behavior.
Methods
Reduction of mGluR1 or mGluR5 activity was evaluated on a variety of behavioral assays in wild-type (WT) and
Fmr1
KO mice through the use of antagonists: JNJ16259685 (JNJ, mGluR1 antagonist) and MPEP (mGluR5 antagonist).
Results
JNJ and MPEP decreased marble burying in both WT and
Fmr1
KO mice without reductions in activity. Neither JNJ nor MPEP affected the prepulse inhibition in either WT or
Fmr1
KO mice. JNJ did not affect
Fmr1
KO motor coordination but did impair WT performance. MPEP improved a measure of motor learning in
Fmr1
KO but not WT mice. While both JNJ and MPEP decreased the audiogenic seizures in the
Fmr1
KO, MPEP completely abolished the manifestation of seizures.
Conclusion
These data illustrate that, while the manipulation of either mGluR1 or mGluR5 can affect select behaviors in the
Fmr1
KO, we observe greater effects upon mGluR5 reduction. |
|---|---|
| AbstractList | Rationale Studies in the Fmrl knockout (KO) mouse, a model of fragile X syndrome (FXS), suggest that excessive signaling through group I metabotropic glutamate receptors (mGluRs), comprised of subtypes mGluR1 and mGluR5, may play a role in the pathogenesis of FXS. Currently, no studies have assessed the effect of mGluR1 modulation on Fmrl KO behavior, and there has not been an extensive behavioral analysis of mGluR5 manipulation in Fmrl KO mice. Objectives The goals for this study were to determine if pharmacologic blockade of mGluR1 may affect Fmrl KO behavior as well as to expand on the current literature regarding pharmacologic blockade of mGluR5 on Fmrl KO behavior. Methods Reduction of mGluR1 or mGluR5 activity was evaluated on a variety of behavioral assays in wild-type (WT) and Fmrl KO mice through the use of antagonists: JNJ16259685 (JNJ, mGluR1 antagonist) and MPEP (mGluR5 antagonist). Results JNJ and MPEP decreased marble burying in both WT and Fmrl KO mice without reductions in activity. Neither JNJ nor MPEP affected the prepulse inhibition in either WT or Fmrl KO mice. JNJ did not affect Fmrl KO motor coordination but did impair WT performance. MPEP improved a measure of motor learning in Fmrl KO but not WT mice. While both JNJ and MPEP decreased the audiogenic seizures in the Fmrl KO, MPEP completely abolished the manifestation of seizures. Conclusion These data illustrate that, while the manipulation of either mGluR1 or mGluR5 can affect select behaviors in the Fmrl KO, we observe greater effects upon mGluR5 reduction. Keywords Fragile X * Fmr1 * Metabotropic glutamate receptor * Mouse * Behavior Rationale: Studies in the Fmr1 knockout (KO) mouse, a model of fragile X syndrome (FXS), suggest that excessive signaling through group I metabotropic glutamate receptors (mGluRs), comprised of subtypes mGluR1 and mGluR5, may play a role in the pathogenesis of FXS. Currently, no studies have assessed the effect of mGluR1 modulation on Fmr1 KO behavior, and there has not been an extensive behavioral analysis of mGluR5 manipulation in Fmr1 KO mice. Objectives: The goals for this study were to determine if pharmacologic blockade of mGluR1 may affect Fmr1 KO behavior as well as to expand on the current literature regarding pharmacologic blockade of mGluR5 on Fmr1 KO behavior. Methods: Reduction of mGluR1 or mGluR5 activity was evaluated on a variety of behavioral assays in wild-type (WT) and Fmr1 KO mice through the use of antagonists: JNJ16259685 (JNJ, mGluR1 antagonist) and MPEP (mGluR5 antagonist). Results: JNJ and MPEP decreased marble burying in both WT and Fmr1 KO mice without reductions in activity. Neither JNJ nor MPEP affected the prepulse inhibition in either WT or Fmr1 KO mice. JNJ did not affect Fmr1 KO motor coordination but did impair WT performance. MPEP improved a measure of motor learning in Fmr1 KO but not WT mice. While both JNJ and MPEP decreased the audiogenic seizures in the Fmr1 KO, MPEP completely abolished the manifestation of seizures. Conclusion: These data illustrate that, while the manipulation of either mGluR1 or mGluR5 can affect select behaviors in the Fmr1 KO, we observe greater effects upon mGluR5 reduction. Studies in the Fmr1 knockout (KO) mouse, a model of fragile X syndrome (FXS), suggest that excessive signaling through group I metabotropic glutamate receptors (mGluRs), comprised of subtypes mGluR1 and mGluR5, may play a role in the pathogenesis of FXS. Currently, no studies have assessed the effect of mGluR1 modulation on Fmr1 KO behavior, and there has not been an extensive behavioral analysis of mGluR5 manipulation in Fmr1 KO mice. The goals for this study were to determine if pharmacologic blockade of mGluR1 may affect Fmr1 KO behavior as well as to expand on the current literature regarding pharmacologic blockade of mGluR5 on Fmr1 KO behavior. Reduction of mGluR1 or mGluR5 activity was evaluated on a variety of behavioral assays in wild-type (WT) and Fmr1 KO mice through the use of antagonists: JNJ16259685 (JNJ, mGluR1 antagonist) and MPEP (mGluR5 antagonist). JNJ and MPEP decreased marble burying in both WT and Fmr1 KO mice without reductions in activity. Neither JNJ nor MPEP affected the prepulse inhibition in either WT or Fmr1 KO mice. JNJ did not affect Fmr1 KO motor coordination but did impair WT performance. MPEP improved a measure of motor learning in Fmr1 KO but not WT mice. While both JNJ and MPEP decreased the audiogenic seizures in the Fmr1 KO, MPEP completely abolished the manifestation of seizures. These data illustrate that, while the manipulation of either mGluR1 or mGluR5 can affect select behaviors in the Fmr1 KO, we observe greater effects upon mGluR5 reduction.[PUBLICATION ABSTRACT] Rationale Studies in the Fmr1 knockout (KO) mouse, a model of fragile X syndrome (FXS), suggest that excessive signaling through group I metabotropic glutamate receptors (mGluRs), comprised of subtypes mGluR1 and mGluR5, may play a role in the pathogenesis of FXS. Currently, no studies have assessed the effect of mGluR1 modulation on Fmr1 KO behavior, and there has not been an extensive behavioral analysis of mGluR5 manipulation in Fmr1 KO mice. Objectives The goals for this study were to determine if pharmacologic blockade of mGluR1 may affect Fmr1 KO behavior as well as to expand on the current literature regarding pharmacologic blockade of mGluR5 on Fmr1 KO behavior. Methods Reduction of mGluR1 or mGluR5 activity was evaluated on a variety of behavioral assays in wild-type (WT) and Fmr1 KO mice through the use of antagonists: JNJ16259685 (JNJ, mGluR1 antagonist) and MPEP (mGluR5 antagonist). Results JNJ and MPEP decreased marble burying in both WT and Fmr1 KO mice without reductions in activity. Neither JNJ nor MPEP affected the prepulse inhibition in either WT or Fmr1 KO mice. JNJ did not affect Fmr1 KO motor coordination but did impair WT performance. MPEP improved a measure of motor learning in Fmr1 KO but not WT mice. While both JNJ and MPEP decreased the audiogenic seizures in the Fmr1 KO, MPEP completely abolished the manifestation of seizures. Conclusion These data illustrate that, while the manipulation of either mGluR1 or mGluR5 can affect select behaviors in the Fmr1 KO, we observe greater effects upon mGluR5 reduction. Studies in the Fmr1 knockout (KO) mouse, a model of fragile X syndrome (FXS), suggest that excessive signaling through group I metabotropic glutamate receptors (mGluRs), comprised of subtypes mGluR1 and mGluR5, may play a role in the pathogenesis of FXS. Currently, no studies have assessed the effect of mGluR1 modulation on Fmr1 KO behavior, and there has not been an extensive behavioral analysis of mGluR5 manipulation in Fmr1 KO mice. The goals for this study were to determine if pharmacologic blockade of mGluR1 may affect Fmr1 KO behavior as well as to expand on the current literature regarding pharmacologic blockade of mGluR5 on Fmr1 KO behavior. Reduction of mGluR1 or mGluR5 activity was evaluated on a variety of behavioral assays in wild-type (WT) and Fmr1 KO mice through the use of antagonists: JNJ16259685 (JNJ, mGluR1 antagonist) and MPEP (mGluR5 antagonist). JNJ and MPEP decreased marble burying in both WT and Fmr1 KO mice without reductions in activity. Neither JNJ nor MPEP affected the prepulse inhibition in either WT or Fmr1 KO mice. JNJ did not affect Fmr1 KO motor coordination but did impair WT performance. MPEP improved a measure of motor learning in Fmr1 KO but not WT mice. While both JNJ and MPEP decreased the audiogenic seizures in the Fmr1 KO, MPEP completely abolished the manifestation of seizures. These data illustrate that, while the manipulation of either mGluR1 or mGluR5 can affect select behaviors in the Fmr1 KO, we observe greater effects upon mGluR5 reduction. |
| Audience | Academic |
| Author | Yuva-Paylor, Lisa A. Perkins, Jennifer R. Paylor, Richard Bui, Nghiem Thomas, Alexia M. |
| Author_xml | – sequence: 1 givenname: Alexia M. surname: Thomas fullname: Thomas, Alexia M. organization: Department of Neuroscience, Baylor College of Medicine – sequence: 2 givenname: Nghiem surname: Bui fullname: Bui, Nghiem organization: Department of Molecular and Human Genetics, Baylor College of Medicine – sequence: 3 givenname: Jennifer R. surname: Perkins fullname: Perkins, Jennifer R. organization: Department of Molecular and Human Genetics, Baylor College of Medicine – sequence: 4 givenname: Lisa A. surname: Yuva-Paylor fullname: Yuva-Paylor, Lisa A. organization: Department of Molecular and Human Genetics, Baylor College of Medicine – sequence: 5 givenname: Richard surname: Paylor fullname: Paylor, Richard email: rpaylor@bcm.edu organization: Department of Neuroscience, Baylor College of Medicine, Department of Molecular and Human Genetics, Baylor College of Medicine |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25589457$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21656124$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kU9rFTEUxYNU7Gv1A7iRoIirqfkzmUyWpWgtFNwouAuZ5GacMpM8k0yh39485mlRNIFkkd-59-SeM3QSYgCEXlJyQQmR7zMhjPKGUNowLkXTPkE72nLWMCLZCdoRwnnDqehP0VnOd6Sutm-foVNGO9FR1u5Quk5x3eMbvEAxQywp7ieLx3ktZjEFcAIL-xITNqGYMYYpl4zNXCDhDDPYggf4bu6nmDKeAjZ4iWuGejqYsa86n8w4zYC_4fwQXIoLPEdPvZkzvDje5-jrxw9frj41t5-vb64ubxsrOlEaZonzgvhB2kGZXpjOUd5SR4gzVDjpLfEgnAWpKKHcSt8T1TvFqe96C8DP0but7j7FHyvkopcpW5hnE6Ca1Ip1vVKEqkq-_ou8i2sK1ZxWlFPZEd5X6M0GjWYGPQVfh2XsoaS-5KIVUgp2oC7-QdXtYJlsjc_XYfwpoJvApphzAq_3aVpMetCU6EPKektZ15T1IWXdVs2ro991WMD9VvyKtQJvj4DJ1sw1g2Cn_MgJ0atqoHJs43J9CiOkx4__v_tPdlbAgg |
| CODEN | PSYPAG |
| CitedBy_id | crossref_primary_10_1007_s12035_022_02933_0 crossref_primary_10_1523_JNEUROSCI_2921_15_2016 crossref_primary_10_1080_13543776_2017_1280466 crossref_primary_10_3389_fmolb_2021_699613 crossref_primary_10_1007_s00213_023_06457_w crossref_primary_10_1097_FBP_0000000000000152 crossref_primary_10_1007_s00702_014_1230_2 crossref_primary_10_3389_fncel_2020_592710 crossref_primary_10_1016_j_bbr_2021_113378 crossref_primary_10_1517_21678707_2013_750240 crossref_primary_10_1101_lm_035956_114 crossref_primary_10_1186_1866_1955_5_20 crossref_primary_10_3390_ijms241914460 crossref_primary_10_1007_s13311_015_0355_9 crossref_primary_10_1016_j_neuron_2012_03_009 crossref_primary_10_1016_j_ntt_2012_08_007 crossref_primary_10_5582_irdr_2014_01024 crossref_primary_10_1002_syn_22069 crossref_primary_10_1016_j_nbd_2018_08_008 crossref_primary_10_1016_j_brainres_2014_05_024 crossref_primary_10_1016_j_bbr_2012_10_059 crossref_primary_10_1038_s41598_021_94967_y crossref_primary_10_1016_j_nbd_2013_09_013 crossref_primary_10_1016_j_bbr_2012_01_031 crossref_primary_10_1007_s00213_014_3464_y crossref_primary_10_1177_10738584211021018 crossref_primary_10_1016_j_neuropharm_2012_07_042 crossref_primary_10_1146_annurev_neuro_060909_153138 crossref_primary_10_1016_j_neuron_2012_03_014 crossref_primary_10_1007_s10803_019_03930_4 crossref_primary_10_1038_nn_3033 crossref_primary_10_1038_npp_2015_66 crossref_primary_10_1016_j_ydbio_2012_11_031 crossref_primary_10_1007_s00702_014_1161_y crossref_primary_10_1371_journal_pone_0077896 crossref_primary_10_1007_s00213_013_3330_3 crossref_primary_10_1038_nn_4592 crossref_primary_10_1523_JNEUROSCI_4761_12_2014 crossref_primary_10_3389_fncel_2014_00081 crossref_primary_10_3390_cells12071004 crossref_primary_10_1523_JNEUROSCI_3246_12_2013 crossref_primary_10_1080_21678707_2013_750240 crossref_primary_10_1542_peds_2016_1159C crossref_primary_10_1097_WCO_0b013e328351823c crossref_primary_10_1371_journal_pone_0070415 crossref_primary_10_3389_fncel_2015_00055 crossref_primary_10_3389_fnmol_2017_00368 crossref_primary_10_3390_molecules28041889 crossref_primary_10_1096_fj_201902435R crossref_primary_10_1007_s00213_019_05367_0 crossref_primary_10_1007_s11064_013_1229_3 crossref_primary_10_1523_ENEURO_0300_19_2019 crossref_primary_10_3389_fncel_2014_00070 crossref_primary_10_1016_j_biopsych_2013_08_003 crossref_primary_10_1523_JNEUROSCI_0886_19_2019 crossref_primary_10_1038_srep19372 crossref_primary_10_1089_cap_2016_0200 crossref_primary_10_1186_s11689_023_09475_z crossref_primary_10_1016_j_bpsgos_2021_08_005 crossref_primary_10_1016_j_biopsych_2013_11_014 crossref_primary_10_1016_j_neuropharm_2012_11_028 crossref_primary_10_1016_j_drudis_2014_01_013 crossref_primary_10_1155_2016_9353929 crossref_primary_10_1186_s11689_015_9134_5 crossref_primary_10_1016_j_brainres_2013_02_038 crossref_primary_10_1016_j_drudis_2013_12_007 crossref_primary_10_1126_scitranslmed_3004218 crossref_primary_10_3390_ijms23073861 crossref_primary_10_3389_fncel_2018_00422 crossref_primary_10_1517_13543776_2013_760544 |
| Cites_doi | 10.1136/jmg.2008.064667 10.1007/BF03033300 10.1016/0092-8674(94)90204-6 10.1016/0014-2999(86)90051-8 10.1152/jn.00383.2005 10.1038/sj.mp.4001432 10.1016/j.tins.2004.04.009 10.1016/S0028-3908(01)00036-3 10.1016/S0306-4522(01)00036-7 10.1038/nrn1763 10.1016/j.nbd.2008.04.002 10.1111/j.1471-4159.2005.03527.x 10.1352/0895-8017(2008)113[44:CSAABI]2.0.CO;2 10.1016/S0028-3908(02)00332-5 10.1016/j.ejphar.2010.03.046 10.1016/S0014-2999(00)00697-X 10.1002/aur.168 10.1542/peds.2008-0317 10.1016/S0006-8993(01)03309-1 10.1016/S0028-3908(00)00113-1 10.1016/j.neuron.2005.01.038 10.1523/JNEUROSCI.0995-04.2004 10.1016/j.neuron.2007.12.001 10.1523/JNEUROSCI.0937-07.2007 10.1111/j.1528-1157.2000.tb01499.x 10.1073/pnas.122205699 10.1093/hmg/9.8.1145 10.1016/j.pharmthera.2005.01.008 10.1037/a0013047 10.1038/372237a0 10.1016/j.neuropharm.2004.08.007 10.1111/j.1601-183X.2004.00087.x 10.1016/j.neuropharm.2006.08.016 10.1016/j.pbb.2010.11.018 10.1016/j.neuron.2005.07.005 10.1016/j.pharmthera.2010.02.008 10.1038/sj.npp.1300540 10.1007/s002130100810 10.1111/j.1460-9568.1996.tb01611.x 10.1016/j.brainres.2004.06.005 10.1016/S0028-3908(99)00082-9 10.1093/hmg/ddl422 10.1074/jbc.M312868200 10.1073/pnas.2336265100 10.1093/hmg/11.5.487 10.1016/j.neuropharm.2005.06.004 10.1038/sj.bjp.0706877 10.1007/s00213-005-2143-4 10.1016/j.neuropharm.2005.01.027 10.1038/sj.bjp.0703923 10.1007/s00213-009-1466-y 10.1016/S0924-8196(00)80044-5 10.1111/j.1476-5381.1991.tb12392.x 10.1152/jn.2001.86.1.321 10.1523/JNEUROSCI.17-13-05196.1997 10.56021/9780801868436 10.1523/JNEUROSCI.22-16-06885.2002 |
| ContentType | Journal Article |
| Copyright | Springer-Verlag 2011 2015 INIST-CNRS COPYRIGHT 2012 Springer Springer-Verlag 2012 |
| Copyright_xml | – notice: Springer-Verlag 2011 – notice: 2015 INIST-CNRS – notice: COPYRIGHT 2012 Springer – notice: Springer-Verlag 2012 |
| DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QG 7QR 7RV 7TK 7X7 7XB 88E 88G 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ K9. KB0 M0S M1P M2M NAPCQ P64 PQEST PQQKQ PQUKI PRINS PSYQQ Q9U |
| DOI | 10.1007/s00213-011-2375-4 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Animal Behavior Abstracts Chemoreception Abstracts Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Psychology Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest One Psychology ProQuest Central Student Technology Research Database ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Chemoreception Abstracts ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition Animal Behavior Abstracts ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest Central (Alumni) |
| DatabaseTitleList | Neurosciences Abstracts ProQuest One Psychology MEDLINE |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-2072 |
| EndPage | 58 |
| ExternalDocumentID | 2550848341 A354577528 10_1007_s00213_011_2375_4 21656124 25589457 |
| Genre | Comparative Study Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIGMS NIH HHS grantid: T32 GM08307 |
| GroupedDBID | -4W -BR .55 3SX 40D 40E 95. 95~ ABMNI AGWIL ALMA_UNASSIGNED_HOLDINGS KOW N2Q R9- RHV SBY SOJ X7M ~EX IQODW --- -56 -5G -EM -Y2 -~C .86 .GJ .VR 04C 06C 06D 0R~ 0VY 123 199 1N0 1SB 2.D 203 28- 29P 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2QV 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 53G 5QI 5RE 5VS 67N 67Z 6NX 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 96X AAAVM AABHQ AACDK AAEOY AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAQLM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDBF ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABIVO ABJNI ABJOX ABKCH ABKTR ABMQK ABNWP ABPLI ABQBU ABSXP ABTAH ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACIPQ ACIWK ACKNC ACMDZ ACMLO ACNCT ACOKC ACOMO ACPRK ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYPR ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFFNX AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN AZQEC B-. B0M BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BMSDO BPHCQ BVXVI CAG CCPQU CGR COF CS3 CSCUP CUY CVF DDRTE DL5 DNIVK DPUIP DU5 DWQXO DXH EAD EAP EBC EBD EBLON EBS ECM EIF EIHBH EIOEI EJD EMB EMK EMOBN EN4 EPAXT EPL EPS ESBYG ESX EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO ICJ IHE IHR IJ- IKXTQ IMOTQ INH INR IPY ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LAS LLZTM M1P M2M M4Y MA- MK0 N9A NAPCQ NB0 NDZJH NPM NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P PF- PQQKQ PROAC PSQYO PSYQQ PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TN5 TSG TSK TSV TUC TUS U2A U9L UAP UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WIP WJK WK6 WK8 WOW XOL YLTOR YQJ YYP Z45 Z7U Z7W Z82 Z83 Z87 Z8O Z8Q Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZY4 ~8M AAYXX CITATION 7QG 7QR 7TK 7XB 8FD 8FK FR3 K9. P64 PQEST PQUKI PRINS Q9U |
| ID | FETCH-LOGICAL-c565t-2c0df50fb7cb9a85a6d1341d00da15d7fc0fe5dce791013c7f8098d931f68cee3 |
| IEDL.DBID | AEJHL |
| ISSN | 0033-3158 |
| IngestDate | Thu Apr 11 20:08:02 EDT 2024 Thu Oct 10 17:25:13 EDT 2024 Tue Nov 19 21:06:55 EST 2024 Tue Nov 12 23:34:38 EST 2024 Fri Aug 23 01:56:05 EDT 2024 Tue Oct 15 23:45:55 EDT 2024 Tue Sep 20 22:38:49 EDT 2022 Wed Oct 12 10:50:00 EDT 2022 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Behavior Mouse Fragile X Metabotropic glutamate receptor Fmr1 Fmrl Chromosome fragility Animal model Group I mglu glutamate receptor Rodentia Glutamate receptor Vertebrata Mammalia Metabotropic receptor Animal Antagonist Fragile X syndrome |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c565t-2c0df50fb7cb9a85a6d1341d00da15d7fc0fe5dce791013c7f8098d931f68cee3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 21656124 |
| PQID | 913176038 |
| PQPubID | 47309 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_926899019 proquest_journals_913176038 gale_infotracmisc_A354577528 gale_infotracacademiconefile_A354577528 crossref_primary_10_1007_s00213_011_2375_4 pubmed_primary_21656124 pascalfrancis_primary_25589457 springer_journals_10_1007_s00213_011_2375_4 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-01-01 |
| PublicationDateYYYYMMDD | 2012-01-01 |
| PublicationDate_xml | – month: 01 year: 2012 text: 2012-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Berlin – name: Germany – name: Heidelberg |
| PublicationTitle | Psychopharmacologia |
| PublicationTitleAbbrev | Psychopharmacology |
| PublicationTitleAlternate | Psychopharmacology (Berl) |
| PublicationYear | 2012 |
| Publisher | Springer-Verlag Springer Springer Nature B.V |
| Publisher_xml | – name: Springer-Verlag – name: Springer – name: Springer Nature B.V |
| References | Pietraszek, Gravius, Schafer, Weil, Trifanova, Danysz (CR45) 2005; 49 Huang, You, Wu, Hsu (CR30) 2004; 279 Spooren, Vassout, Neijt, Kuhn, Gasparini, Roux, Porsolt, Gentsch (CR51) 2000; 295 Tucker, Richards, Lardelli (CR55) 2006; 15 Henry, Lehmann-Masten, Gasparini, Geyer, Markou (CR25) 2002; 43 Volk, Daly, Huber (CR57) 2006; 95 Thomas, Burant, Bui, Graham, Yuva-Paylor, Paylor (CR53) 2009; 204 D’Hulst, Kooy (CR13) 2009; 46 Aiba, Kano, Chen, Stanton, Fox, Herrup, Zwingman, Tonegawa (CR1) 1994; 79 Bates, Harper, Jones (CR3) 2002 Broekkamp, Rijk, Joly-Gelouin, Lloyd (CR8) 1986; 126 Conn, Battaglia, Marino, Nicoletti (CR11) 2005; 6 Conquet, Bashir, Davies, Daniel, Ferraguti, Bordi, Franz-Bacon, Reggiani, Matarese, Condé, Collingridge, Crepel (CR12) 1994; 372 McBride, Choi, Wang, Liebelt, Braunstein, Ferreiro, Sehgal, Siwicki, Dockendorff, Nguyen, McDonald, Jongens (CR38) 2005; 45 Muddashetty, Kelić, Gross, Xu, Bassell (CR39) 2007; 27 Faas, Adwanikar, Gereau, Saggau (CR19) 2002; 22 Koekkoek, Yamaguchi, Milojkovic, Dortland, Ruigrok, Maex, De Graaf, Smit, VanderWerf, Bakker, Willemsen, Ikeda, Kakizawa, Onodera, Nelson, Mientjes, Joosten, De Schutter, Oostra, Ito, De Zeeuw (CR34) 2005; 47 Hagerman, Hagerman (CR22) 2002 Huber, Roder, Bear (CR31) 2001; 86 Spencer, Alekseyenko, Hamilton, Thomas, Serysheva, Yuva-Paylor, Paylor (CR49) 2011; 4 Frankland, Wang, Rosner, Shimizu, Balleine, Dykens, Ornitz, Silva (CR20) 2004; 9 Yan, Asafo-Adjei, Arnold, Brown, Bauchwitz (CR59) 2004; 3 Hagerman, Berry-Kravis, Kaufmann, Ono, Tartaglia, Lachiewicz, Kronk, Delahunty, Hessl, Visootsak, Picker, Gane, Tranfaglia (CR23) 2009; 123 Njung’e, Handley (CR42) 1991; 104 Hikichi, Nishino, Fukushima, Satow, Maehara, Kawamoto, Ohta (CR26) 2010; 639 Lujan, Nusser, Roberts, Shigemoto, Somogyi (CR37) 1996; 8 Bontekoe, McIlwain, Nieuwenhuizen, Yuva-Paylor, Nellis, Willemsen, Fang, Kirkpatrick, Bakker, McAninch, Cheng, Merriweather, Hoogeveen, Nelson, Paylor, Oostra (CR5) 2002; 11 Brody, Geyer (CR7) 2004; 6 Spooren, Gasparini, Bergmann, Kuhn (CR50) 2000; 406 Bear, Huber, Warren (CR4) 2004; 27 Bakker, Verheij, Willemsen, van der Helm, Oerlemans, Vermey, Bygrave, Hoogeveen, Oostra, Reyniers, De Boule, D’Hooge, Cras, van Velzen, Nagels, Martin, De Deyn, Darby, Willems (CR2) 1994; 78 Dolen, Osterweil, Rao, Smith, Auerbach, Chattarji, Bear (CR16) 2007; 56 Musumeci, Bosco, Calabrese, Bakker, De Sarro, Elia, Ferri, Oostra (CR40) 2000; 41 Braff, Geyer, Swerdlow (CR6) 2001; 156 Hall, Lightbody, Reiss (CR24) 2008; 113 Hou, Klann (CR28) 2004; 24 Schiefer, Sprünken, Puls, Lüesse, Milkereit, Milkereit, Johann, Kosinski (CR46) 2004; 1019 Huber, Gallagher, Warren, Bear (CR32) 2002; 99 Todd, Mack, Malter (CR54) 2003; 100 Huang, Hsu (CR29) 2006; 96 Zou, Huang, Wu, Li (CR61) 2007; 52 Peier, McIlwain, Kenneson, Warren, Paylor, Nelson (CR44) 2000; 9 Schulz, Fendt, Gasparini, Lingenhohl, Kuhn, Koch (CR47) 2001; 41 Nielsen, Derber, McClellan, Crnic (CR41) 2002; 927 Yan, Rammal, Tranfaglia, Bauchwitz (CR60) 2005; 49 Gasparini, Lingenhöhl, Stoehr, Flor, Heinrich, Vranesic, Biollaz, Allgeier, Heckendorn, Urwyler, Varney, Johnson, Hess, Rao, Sacaan, Santori, Veliçelebi, Kuhn (CR21) 1999; 38 Hodgson, Hyde, Guthrie, Cohen-Williams, Leach, Kazdoba, Bleickardt, Lu, Parker, Varty (CR27) 2011; 98 El-Kouhen, Lehto, Pan, Chang, Baker, Zhong, Hollingsworth, Mikusa, Cronin, Chu, McGaraughty, Uchic, Miller, Rodell, Patel, Bhatia, Mezler, Kolasa, Zheng, Fox, Stewart, Decker, Moreland, Brioni, Honore (CR18) 2006; 149 Shigemoto, Mizuno (CR48) 2000; 18 Busse, Brodkin, Tattersall, Anderson, Warren, Tehrani, Bristow, Varney, Cosford (CR9) 2004; 29 Dhami, Ferguson (CR15) 2006; 111 Lu, Jia, Janus, Henderson, Gerlai, Wojtowicz, Roder (CR36) 1997; 17 Lavreysen, Wouters, Bischoff, Nóbrega Pereira, Langlois, Blokland, Somers, Dillen, Lesage (CR35) 2004; 47 Kandel, Schwartz, Jessell (CR33) 2000 Varty, Grilli, Forlani, Fredduzzi, Grzelak, Guthrie, Hodgson, Lu, Nicolussi, Pond, Parker, Hunter, Higgins, Reggiani, Bertorelli (CR56) 2005; 179 Chen, Toth (CR10) 2001; 103 Tatarczyńska, Kłodzińska, Chojnacka-Wójcik, Pałucha, Gasparini, Kuhn, Pilc (CR52) 2001; 132 Paylor, Yuva-Paylor, Nelson, Spencer (CR43) 2008; 122 Walker, Bowes, Panesar, Davis, Gentry, Kesingland, Gasparini, Spooren, Stoehr, Pagano, Flor, Vranesic, Lingenhoehl, Johnson, Varney, Urban, Kuhn (CR58) 2001; 40 Dolen, Carpenter, Ocain, Bear (CR17) 2010; 127 de Vrij, Levenga, van der Linde, Koekkoek, De Zeeuw, Nelson, Oostra, Willemsen (CR14) 2008; 31 19045956 - Behav Neurosci. 2008 Dec;122(6):1371-7 8758956 - Eur J Neurosci. 1996 Jul;8(7):1488-500 21268289 - Autism Res. 2011 Feb;4(1):40-56 17065172 - Hum Mol Genet. 2006 Dec 1;15(23 ):3446-58 11431513 - J Neurophysiol. 2001 Jul;86(1):321-5 7954803 - Cell. 1994 Oct 21;79(2):377-88 17016515 - Br J Pharmacol. 2006 Nov;149(6):761-74 15254091 - J Neurosci. 2004 Jul 14;24(28):6352-61 15306259 - Brain Res. 2004 Sep 3;1019(1-2):246-54 10767339 - Hum Mol Genet. 2000 May 1;9(8):1145-59 11077065 - Neuropharmacology. 2001;40(1):1-9 15544577 - Genes Brain Behav. 2004 Dec;3(6):337-59 20303363 - Pharmacol Ther. 2010 Jul;127(1):78-93 16054174 - Neuropharmacology. 2005 Dec;49(7):1053-66 12177186 - J Neurosci. 2002 Aug 15;22(16):6885-90 11875043 - Hum Mol Genet. 2002 Mar 1;11(5):487-98 11549226 - Psychopharmacology (Berl). 2001 Jul;156(2-3):234-58 20371235 - Eur J Pharmacol. 2010 Aug 10;639(1-3):99-105 19117905 - Pediatrics. 2009 Jan;123(1):378-90 11264235 - Br J Pharmacol. 2001 Apr;132(7):1423-30 21122808 - Pharmacol Biochem Behav. 2011 Apr;98(2):181-7 15748850 - Neuron. 2005 Mar 3;45(5):753-64 17011597 - Neuropharmacology. 2007 Feb;52(2):476-86 11301211 - Neuroscience. 2001;103(4):1043-50 18173299 - Am J Ment Retard. 2008 Jan;113(1):44-53 11814427 - Brain Res. 2002 Feb 8;927(1):8-17 10530811 - Neuropharmacology. 1999 Oct;38(10 ):1493-503 11082464 - J Pharmacol Exp Ther. 2000 Dec;295(3):1267-75 11445180 - Neuropharmacology. 2001 Jul;41(1):1-7 16421200 - J Neurophysiol. 2006 Apr;95(4):2427-38 14709549 - J Biol Chem. 2004 Mar 26;279(13):12286-92 15184109 - Neurotox Res. 2004;6(1):79-90 15682298 - Psychopharmacology (Berl). 2005 Apr;179(1):207-17 11040347 - Eur J Pharmacol. 2000 Oct 20;406(3):403-10 12032354 - Proc Natl Acad Sci U S A. 2002 May 28;99(11):7746-50 16055059 - Neuron. 2005 Aug 4;47(3):339-52 16277605 - J Neurochem. 2006 Jan;96(1):179-94 15219735 - Trends Neurosci. 2004 Jul;27(7):370-7 15555631 - Neuropharmacology. 2004 Dec;47(7):961-72 12527469 - Neuropharmacology. 2002 Dec;43(8):1199-209 18093519 - Neuron. 2007 Dec 20;56(6):955-62 16574233 - Pharmacol Ther. 2006 Jul;111(1):260-71 1686200 - Br J Pharmacol. 1991 Sep;104(1):105-12 14614133 - Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14374-8 18571098 - Neurobiol Dis. 2008 Jul;31(1):127-32 10643918 - Epilepsia. 2000 Jan;41(1):19-23 2875886 - Eur J Pharmacol. 1986 Jul 31;126(3):223-9 14981523 - Mol Psychiatry. 2004 Apr;9(4):417-25 19189082 - Psychopharmacology (Berl). 2009 Jun;204(2):361-73 19724010 - J Med Genet. 2009 Sep;46(9):577-84 16276355 - Nat Rev Neurosci. 2005 Oct;6(10):787-98 9185557 - J Neurosci. 1997 Jul 1;17(13):5196-205 15992582 - Neuropharmacology. 2005 Jul;49(1):73-85 15305166 - Neuropsychopharmacology. 2004 Nov;29(11):1971-9 17507556 - J Neurosci. 2007 May 16;27(20):5338-48 7969468 - Nature. 1994 Nov 17;372(6503):237-43 L Hou (2375_CR28) 2004; 24 CC Huang (2375_CR29) 2006; 96 CJ Bontekoe (2375_CR5) 2002; 11 E Tatarczyńska (2375_CR52) 2001; 132 F Gasparini (2375_CR21) 1999; 38 RJ Hagerman (2375_CR22) 2002 CC Huang (2375_CR30) 2004; 279 SM McBride (2375_CR38) 2005; 45 SKE Koekkoek (2375_CR34) 2005; 47 L Chen (2375_CR10) 2001; 103 B Tucker (2375_CR55) 2006; 15 G Faas (2375_CR19) 2002; 22 C D’Hulst (2375_CR13) 2009; 46 KM Huber (2375_CR32) 2002; 99 RA Hodgson (2375_CR27) 2011; 98 ER Kandel (2375_CR33) 2000 O El-Kouhen (2375_CR18) 2006; 149 PJ Conn (2375_CR11) 2005; 6 J Schiefer (2375_CR46) 2004; 1019 A Aiba (2375_CR1) 1994; 79 AM Peier (2375_CR44) 2000; 9 WPJM Spooren (2375_CR50) 2000; 406 K Njung’e (2375_CR42) 1991; 104 LJ Volk (2375_CR57) 2006; 95 R Lujan (2375_CR37) 1996; 8 R Paylor (2375_CR43) 2008; 122 GB Varty (2375_CR56) 2005; 179 PW Frankland (2375_CR20) 2004; 9 RS Muddashetty (2375_CR39) 2007; 27 DM Nielsen (2375_CR41) 2002; 927 CS Busse (2375_CR9) 2004; 29 DL Braff (2375_CR6) 2001; 156 FMS Vrij de (2375_CR14) 2008; 31 B Schulz (2375_CR47) 2001; 41 CE Bakker (2375_CR2) 1994; 78 G Dolen (2375_CR16) 2007; 56 G Dolen (2375_CR17) 2010; 127 D Zou (2375_CR61) 2007; 52 R Shigemoto (2375_CR48) 2000; 18 SS Hall (2375_CR24) 2008; 113 M Pietraszek (2375_CR45) 2005; 49 G Bates (2375_CR3) 2002 CL Broekkamp (2375_CR8) 1986; 126 SA Henry (2375_CR25) 2002; 43 WPJM Spooren (2375_CR51) 2000; 295 RJ Hagerman (2375_CR23) 2009; 123 F Conquet (2375_CR12) 1994; 372 PK Todd (2375_CR54) 2003; 100 A Thomas (2375_CR53) 2009; 204 H Lavreysen (2375_CR35) 2004; 47 QJ Yan (2375_CR59) 2004; 3 CM Spencer (2375_CR49) 2011; 4 K Walker (2375_CR58) 2001; 40 YM Lu (2375_CR36) 1997; 17 QJ Yan (2375_CR60) 2005; 49 GK Dhami (2375_CR15) 2006; 111 SA Musumeci (2375_CR40) 2000; 41 KM Huber (2375_CR31) 2001; 86 MF Bear (2375_CR4) 2004; 27 H Hikichi (2375_CR26) 2010; 639 SA Brody (2375_CR7) 2004; 6 |
| References_xml | – volume: 46 start-page: 577 year: 2009 end-page: 584 ident: CR13 article-title: Fragile X syndrome: from molecular genetics to therapy publication-title: J Med Genet doi: 10.1136/jmg.2008.064667 contributor: fullname: Kooy – volume: 6 start-page: 79 year: 2004 end-page: 90 ident: CR7 article-title: Interactions of the mGluR5 gene with breeding and maternal factors on startle and prepulse inhibition in mice publication-title: Neurotox Res doi: 10.1007/BF03033300 contributor: fullname: Geyer – volume: 79 start-page: 377 year: 1994 end-page: 388 ident: CR1 article-title: Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice publication-title: Cell doi: 10.1016/0092-8674(94)90204-6 contributor: fullname: Tonegawa – volume: 126 start-page: 223 year: 1986 end-page: 229 ident: CR8 article-title: Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice publication-title: Eur J Pharmacol doi: 10.1016/0014-2999(86)90051-8 contributor: fullname: Lloyd – volume: 95 start-page: 2427 year: 2006 end-page: 2438 ident: CR57 article-title: Differential roles for group I mGluR subtypes in induction and expression of chemically induced hippocampal long-term depression publication-title: J Neurophysiol doi: 10.1152/jn.00383.2005 contributor: fullname: Huber – volume: 9 start-page: 417 year: 2004 end-page: 425 ident: CR20 article-title: Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice publication-title: Mol Psychiatry doi: 10.1038/sj.mp.4001432 contributor: fullname: Silva – volume: 27 start-page: 370 year: 2004 end-page: 377 ident: CR4 article-title: The mGluR theory of fragile X mental retardation publication-title: Trends Neurosci doi: 10.1016/j.tins.2004.04.009 contributor: fullname: Warren – volume: 41 start-page: 1 year: 2001 end-page: 7 ident: CR47 article-title: The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats publication-title: Neuropharmacology doi: 10.1016/S0028-3908(01)00036-3 contributor: fullname: Koch – volume: 104 start-page: 105 year: 1991 end-page: 112 ident: CR42 article-title: Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents publication-title: Br J Pharmacol contributor: fullname: Handley – volume: 78 start-page: 23 year: 1994 end-page: 33 ident: CR2 article-title: Fmr1 knockout mice: a model to study fragile X mental retardation publication-title: Cell contributor: fullname: Willems – volume: 103 start-page: 1043 year: 2001 end-page: 1050 ident: CR10 article-title: Fragile X mice develop sensory hyperreactivity to auditory stimuli publication-title: Neuroscience doi: 10.1016/S0306-4522(01)00036-7 contributor: fullname: Toth – volume: 6 start-page: 787 year: 2005 end-page: 798 ident: CR11 article-title: Metabotropic glutamate receptors in the basal ganglia motor circuit publication-title: Nat Rev Neurosci doi: 10.1038/nrn1763 contributor: fullname: Nicoletti – volume: 31 start-page: 127 year: 2008 end-page: 132 ident: CR14 article-title: Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2008.04.002 contributor: fullname: Willemsen – volume: 96 start-page: 179 year: 2006 end-page: 194 ident: CR29 article-title: Sustained activation of metabotropic glutamate receptor 5 and protein tyrosine phosphatases mediate the expression of ( )-3,5-dihydroxyphenylglycine-induced long-term depression in the hippocampal CA1 region publication-title: J Neurochem doi: 10.1111/j.1471-4159.2005.03527.x contributor: fullname: Hsu – volume: 113 start-page: 44 year: 2008 end-page: 53 ident: CR24 article-title: Compulsive, self-injurious, and autistic behavior in children and adolescents with fragile X syndrome publication-title: Am J Ment Retard doi: 10.1352/0895-8017(2008)113[44:CSAABI]2.0.CO;2 contributor: fullname: Reiss – volume: 43 start-page: 1199 year: 2002 end-page: 1209 ident: CR25 article-title: The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity publication-title: Neuropharmacology doi: 10.1016/S0028-3908(02)00332-5 contributor: fullname: Markou – volume: 295 start-page: 1267 year: 2000 end-page: 1275 ident: CR51 article-title: Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents publication-title: J Pharmacol Exp Ther contributor: fullname: Gentsch – volume: 639 start-page: 99 year: 2010 end-page: 105 ident: CR26 article-title: Pharmacological effects of metabotropic glutamate receptor ligands on prepulse inhibition in DBA/2J mice publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2010.03.046 contributor: fullname: Ohta – volume: 22 start-page: 6885 year: 2002 end-page: 6890 ident: CR19 article-title: Modulation of presynaptic calcium transients by metabotropic glutamate receptor activation: a differential role in acute depression of synaptic transmission and long-term depression publication-title: J Neurosci contributor: fullname: Saggau – volume: 86 start-page: 321 year: 2001 end-page: 325 ident: CR31 article-title: Chemical induction of mGluR5- and protein synthesis-dependent long-term depression in hippocampal area CA1 publication-title: J Neurophysiol contributor: fullname: Bear – volume: 406 start-page: 403 year: 2000 end-page: 410 ident: CR50 article-title: Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats publication-title: Eur J Pharmacol doi: 10.1016/S0014-2999(00)00697-X contributor: fullname: Kuhn – volume: 4 start-page: 40 year: 2011 end-page: 56 ident: CR49 article-title: Modifying behavioral phenotypes in Fmr1 KO mice: genetic background differences reveal autistic-like responses publication-title: Autism Res doi: 10.1002/aur.168 contributor: fullname: Paylor – volume: 123 start-page: 378 year: 2009 end-page: 390 ident: CR23 article-title: Advances in the treatment of fragile X syndrome publication-title: Pediatrics doi: 10.1542/peds.2008-0317 contributor: fullname: Tranfaglia – volume: 927 start-page: 8 year: 2002 end-page: 17 ident: CR41 article-title: Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome publication-title: Brain Res doi: 10.1016/S0006-8993(01)03309-1 contributor: fullname: Crnic – volume: 40 start-page: 1 year: 2001 end-page: 9 ident: CR58 article-title: Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain publication-title: Neuropharmacology doi: 10.1016/S0028-3908(00)00113-1 contributor: fullname: Kuhn – volume: 45 start-page: 753 year: 2005 end-page: 764 ident: CR38 article-title: Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a model of fragile X syndrome publication-title: Neuron doi: 10.1016/j.neuron.2005.01.038 contributor: fullname: Jongens – volume: 24 start-page: 6352 year: 2004 end-page: 6361 ident: CR28 article-title: Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression publication-title: J Neurosci doi: 10.1523/JNEUROSCI.0995-04.2004 contributor: fullname: Klann – volume: 56 start-page: 955 year: 2007 end-page: 962 ident: CR16 article-title: Correction of fragile X syndrome in mice publication-title: Neuron doi: 10.1016/j.neuron.2007.12.001 contributor: fullname: Bear – volume: 27 start-page: 5338 year: 2007 end-page: 5348 ident: CR39 article-title: Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome publication-title: J Neurosci doi: 10.1523/JNEUROSCI.0937-07.2007 contributor: fullname: Bassell – volume: 41 start-page: 19 year: 2000 end-page: 23 ident: CR40 article-title: Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome publication-title: Epilepsia doi: 10.1111/j.1528-1157.2000.tb01499.x contributor: fullname: Oostra – volume: 99 start-page: 7746 year: 2002 end-page: 7750 ident: CR32 article-title: Altered synaptic plasticity in a mouse model of fragile X mental retardation publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.122205699 contributor: fullname: Bear – volume: 9 start-page: 1145 year: 2000 end-page: 1159 ident: CR44 article-title: (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features publication-title: Hum Mol Genet doi: 10.1093/hmg/9.8.1145 contributor: fullname: Nelson – volume: 111 start-page: 260 year: 2006 end-page: 271 ident: CR15 article-title: Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2005.01.008 contributor: fullname: Ferguson – volume: 122 start-page: 1371 year: 2008 end-page: 1377 ident: CR43 article-title: Reversal of sensorimotor gating abnormalities in Fmr1 knockout mice carrying a human FMR1 transgene publication-title: Behav Neurosci doi: 10.1037/a0013047 contributor: fullname: Spencer – volume: 372 start-page: 237 year: 1994 end-page: 243 ident: CR12 article-title: Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1 publication-title: Nature doi: 10.1038/372237a0 contributor: fullname: Crepel – volume: 47 start-page: 961 year: 2004 end-page: 972 ident: CR35 article-title: JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2004.08.007 contributor: fullname: Lesage – volume: 3 start-page: 337 year: 2004 end-page: 359 ident: CR59 article-title: A phenotypic and molecular characterization of the fmr1-tm1Cgr Fragile X mouse publication-title: Genes Brain Behav doi: 10.1111/j.1601-183X.2004.00087.x contributor: fullname: Bauchwitz – volume: 52 start-page: 476 year: 2007 end-page: 486 ident: CR61 article-title: Metabotropic glutamate subtype 5 receptors modulate fear-conditioning induced enhancement of prepulse inhibition in rats publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2006.08.016 contributor: fullname: Li – volume: 98 start-page: 181 year: 2011 end-page: 187 ident: CR27 article-title: Characterization of the selective mGluR1 antagonist, JNJ16259685, in rodent models of movement and coordination publication-title: Pharmacol Biochem Behav doi: 10.1016/j.pbb.2010.11.018 contributor: fullname: Varty – start-page: 832 year: 2000 end-page: 852 ident: CR33 publication-title: The cerebellum. Principles of neural science contributor: fullname: Jessell – volume: 47 start-page: 339 year: 2005 end-page: 352 ident: CR34 article-title: Deletion of FMR1 in purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in fragile X syndrome publication-title: Neuron doi: 10.1016/j.neuron.2005.07.005 contributor: fullname: De Zeeuw – year: 2002 ident: CR3 publication-title: Huntington’s disease contributor: fullname: Jones – volume: 127 start-page: 78 year: 2010 end-page: 93 ident: CR17 article-title: Mechanism-based approaches to treating fragile X publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2010.02.008 contributor: fullname: Bear – volume: 29 start-page: 1971 year: 2004 end-page: 1979 ident: CR9 article-title: The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1300540 contributor: fullname: Cosford – volume: 156 start-page: 234 year: 2001 end-page: 258 ident: CR6 article-title: Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies publication-title: Psychopharmacology (Berl) doi: 10.1007/s002130100810 contributor: fullname: Swerdlow – volume: 8 start-page: 1488 year: 1996 end-page: 1500 ident: CR37 article-title: Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus publication-title: Eur J Neurosci doi: 10.1111/j.1460-9568.1996.tb01611.x contributor: fullname: Somogyi – volume: 1019 start-page: 246 year: 2004 end-page: 254 ident: CR46 article-title: The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease publication-title: Brain Res doi: 10.1016/j.brainres.2004.06.005 contributor: fullname: Kosinski – volume: 38 start-page: 1493 year: 1999 end-page: 1503 ident: CR21 article-title: 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist publication-title: Neuropharmacology doi: 10.1016/S0028-3908(99)00082-9 contributor: fullname: Kuhn – year: 2002 ident: CR22 publication-title: Fragile X syndrome: diagnosis, treatment, and research contributor: fullname: Hagerman – volume: 15 start-page: 3446 year: 2006 end-page: 3458 ident: CR55 article-title: Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome publication-title: Hum Mol Genet doi: 10.1093/hmg/ddl422 contributor: fullname: Lardelli – volume: 17 start-page: 5196 year: 1997 end-page: 5205 ident: CR36 article-title: Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP publication-title: J Neurosci contributor: fullname: Roder – volume: 279 start-page: 12286 year: 2004 end-page: 12292 ident: CR30 article-title: Rap1-induced p38 mitogen-activated protein kinase activation facilitates AMPA receptor trafficking via the GDI.Rab5 complex. Potential role in ( )-3,5-dihydroxyphenylglycene-induced long term depression publication-title: J Biol Chem doi: 10.1074/jbc.M312868200 contributor: fullname: Hsu – volume: 100 start-page: 14374 year: 2003 end-page: 14378 ident: CR54 article-title: The fragile X mental retardation protein is required for type-I metabotropic glutamate receptor-dependent translation of PSD-95 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.2336265100 contributor: fullname: Malter – volume: 11 start-page: 487 year: 2002 end-page: 498 ident: CR5 article-title: Knockout mouse model for Fxr2: a model for mental retardation publication-title: Hum Mol Genet doi: 10.1093/hmg/11.5.487 contributor: fullname: Oostra – volume: 49 start-page: 1053 year: 2005 end-page: 1066 ident: CR60 article-title: Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2005.06.004 contributor: fullname: Bauchwitz – volume: 149 start-page: 761 year: 2006 end-page: 774 ident: CR18 article-title: Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0706877 contributor: fullname: Honore – volume: 179 start-page: 207 year: 2005 end-page: 217 ident: CR56 article-title: The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-005-2143-4 contributor: fullname: Bertorelli – volume: 49 start-page: 73 year: 2005 end-page: 85 ident: CR45 article-title: mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2005.01.027 contributor: fullname: Danysz – volume: 132 start-page: 1423 year: 2001 end-page: 1430 ident: CR52 article-title: Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0703923 contributor: fullname: Pilc – volume: 204 start-page: 361 year: 2009 end-page: 373 ident: CR53 article-title: Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-009-1466-y contributor: fullname: Paylor – volume: 18 start-page: 63 year: 2000 end-page: 98 ident: CR48 article-title: Metabotropic glutamate receptors—immunocytochemical and in situ hybridization analyses publication-title: Handb Chem Neuroanat doi: 10.1016/S0924-8196(00)80044-5 contributor: fullname: Mizuno – volume: 41 start-page: 19 year: 2000 ident: 2375_CR40 publication-title: Epilepsia doi: 10.1111/j.1528-1157.2000.tb01499.x contributor: fullname: SA Musumeci – volume: 279 start-page: 12286 year: 2004 ident: 2375_CR30 publication-title: J Biol Chem doi: 10.1074/jbc.M312868200 contributor: fullname: CC Huang – volume: 1019 start-page: 246 year: 2004 ident: 2375_CR46 publication-title: Brain Res doi: 10.1016/j.brainres.2004.06.005 contributor: fullname: J Schiefer – volume: 41 start-page: 1 year: 2001 ident: 2375_CR47 publication-title: Neuropharmacology doi: 10.1016/S0028-3908(01)00036-3 contributor: fullname: B Schulz – volume: 104 start-page: 105 year: 1991 ident: 2375_CR42 publication-title: Br J Pharmacol doi: 10.1111/j.1476-5381.1991.tb12392.x contributor: fullname: K Njung’e – volume: 46 start-page: 577 year: 2009 ident: 2375_CR13 publication-title: J Med Genet doi: 10.1136/jmg.2008.064667 contributor: fullname: C D’Hulst – volume: 99 start-page: 7746 year: 2002 ident: 2375_CR32 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.122205699 contributor: fullname: KM Huber – volume: 179 start-page: 207 year: 2005 ident: 2375_CR56 publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-005-2143-4 contributor: fullname: GB Varty – volume: 78 start-page: 23 year: 1994 ident: 2375_CR2 publication-title: Cell contributor: fullname: CE Bakker – volume: 95 start-page: 2427 year: 2006 ident: 2375_CR57 publication-title: J Neurophysiol doi: 10.1152/jn.00383.2005 contributor: fullname: LJ Volk – volume: 132 start-page: 1423 year: 2001 ident: 2375_CR52 publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0703923 contributor: fullname: E Tatarczyńska – volume: 43 start-page: 1199 year: 2002 ident: 2375_CR25 publication-title: Neuropharmacology doi: 10.1016/S0028-3908(02)00332-5 contributor: fullname: SA Henry – volume: 96 start-page: 179 year: 2006 ident: 2375_CR29 publication-title: J Neurochem doi: 10.1111/j.1471-4159.2005.03527.x contributor: fullname: CC Huang – volume: 56 start-page: 955 year: 2007 ident: 2375_CR16 publication-title: Neuron doi: 10.1016/j.neuron.2007.12.001 contributor: fullname: G Dolen – volume: 11 start-page: 487 year: 2002 ident: 2375_CR5 publication-title: Hum Mol Genet doi: 10.1093/hmg/11.5.487 contributor: fullname: CJ Bontekoe – volume: 86 start-page: 321 year: 2001 ident: 2375_CR31 publication-title: J Neurophysiol doi: 10.1152/jn.2001.86.1.321 contributor: fullname: KM Huber – volume: 126 start-page: 223 year: 1986 ident: 2375_CR8 publication-title: Eur J Pharmacol doi: 10.1016/0014-2999(86)90051-8 contributor: fullname: CL Broekkamp – volume: 100 start-page: 14374 year: 2003 ident: 2375_CR54 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.2336265100 contributor: fullname: PK Todd – volume: 24 start-page: 6352 year: 2004 ident: 2375_CR28 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.0995-04.2004 contributor: fullname: L Hou – volume: 127 start-page: 78 year: 2010 ident: 2375_CR17 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2010.02.008 contributor: fullname: G Dolen – volume: 149 start-page: 761 year: 2006 ident: 2375_CR18 publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0706877 contributor: fullname: O El-Kouhen – volume: 156 start-page: 234 year: 2001 ident: 2375_CR6 publication-title: Psychopharmacology (Berl) doi: 10.1007/s002130100810 contributor: fullname: DL Braff – volume: 113 start-page: 44 year: 2008 ident: 2375_CR24 publication-title: Am J Ment Retard doi: 10.1352/0895-8017(2008)113[44:CSAABI]2.0.CO;2 contributor: fullname: SS Hall – volume: 47 start-page: 961 year: 2004 ident: 2375_CR35 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2004.08.007 contributor: fullname: H Lavreysen – volume: 9 start-page: 1145 year: 2000 ident: 2375_CR44 publication-title: Hum Mol Genet doi: 10.1093/hmg/9.8.1145 contributor: fullname: AM Peier – volume-title: Huntington’s disease year: 2002 ident: 2375_CR3 contributor: fullname: G Bates – volume: 9 start-page: 417 year: 2004 ident: 2375_CR20 publication-title: Mol Psychiatry doi: 10.1038/sj.mp.4001432 contributor: fullname: PW Frankland – volume: 45 start-page: 753 year: 2005 ident: 2375_CR38 publication-title: Neuron doi: 10.1016/j.neuron.2005.01.038 contributor: fullname: SM McBride – volume: 49 start-page: 73 year: 2005 ident: 2375_CR45 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2005.01.027 contributor: fullname: M Pietraszek – volume: 295 start-page: 1267 year: 2000 ident: 2375_CR51 publication-title: J Pharmacol Exp Ther contributor: fullname: WPJM Spooren – volume: 111 start-page: 260 year: 2006 ident: 2375_CR15 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2005.01.008 contributor: fullname: GK Dhami – volume: 98 start-page: 181 year: 2011 ident: 2375_CR27 publication-title: Pharmacol Biochem Behav doi: 10.1016/j.pbb.2010.11.018 contributor: fullname: RA Hodgson – volume: 15 start-page: 3446 year: 2006 ident: 2375_CR55 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddl422 contributor: fullname: B Tucker – volume: 6 start-page: 787 year: 2005 ident: 2375_CR11 publication-title: Nat Rev Neurosci doi: 10.1038/nrn1763 contributor: fullname: PJ Conn – volume: 79 start-page: 377 year: 1994 ident: 2375_CR1 publication-title: Cell doi: 10.1016/0092-8674(94)90204-6 contributor: fullname: A Aiba – volume: 123 start-page: 378 year: 2009 ident: 2375_CR23 publication-title: Pediatrics doi: 10.1542/peds.2008-0317 contributor: fullname: RJ Hagerman – start-page: 832 volume-title: The cerebellum. Principles of neural science year: 2000 ident: 2375_CR33 contributor: fullname: ER Kandel – volume: 4 start-page: 40 year: 2011 ident: 2375_CR49 publication-title: Autism Res doi: 10.1002/aur.168 contributor: fullname: CM Spencer – volume: 27 start-page: 5338 year: 2007 ident: 2375_CR39 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.0937-07.2007 contributor: fullname: RS Muddashetty – volume: 6 start-page: 79 year: 2004 ident: 2375_CR7 publication-title: Neurotox Res doi: 10.1007/BF03033300 contributor: fullname: SA Brody – volume: 17 start-page: 5196 year: 1997 ident: 2375_CR36 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.17-13-05196.1997 contributor: fullname: YM Lu – volume: 103 start-page: 1043 year: 2001 ident: 2375_CR10 publication-title: Neuroscience doi: 10.1016/S0306-4522(01)00036-7 contributor: fullname: L Chen – volume: 204 start-page: 361 year: 2009 ident: 2375_CR53 publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-009-1466-y contributor: fullname: A Thomas – volume: 52 start-page: 476 year: 2007 ident: 2375_CR61 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2006.08.016 contributor: fullname: D Zou – volume: 31 start-page: 127 year: 2008 ident: 2375_CR14 publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2008.04.002 contributor: fullname: FMS Vrij de – volume-title: Fragile X syndrome: diagnosis, treatment, and research year: 2002 ident: 2375_CR22 doi: 10.56021/9780801868436 contributor: fullname: RJ Hagerman – volume: 47 start-page: 339 year: 2005 ident: 2375_CR34 publication-title: Neuron doi: 10.1016/j.neuron.2005.07.005 contributor: fullname: SKE Koekkoek – volume: 27 start-page: 370 year: 2004 ident: 2375_CR4 publication-title: Trends Neurosci doi: 10.1016/j.tins.2004.04.009 contributor: fullname: MF Bear – volume: 122 start-page: 1371 year: 2008 ident: 2375_CR43 publication-title: Behav Neurosci doi: 10.1037/a0013047 contributor: fullname: R Paylor – volume: 22 start-page: 6885 year: 2002 ident: 2375_CR19 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.22-16-06885.2002 contributor: fullname: G Faas – volume: 639 start-page: 99 year: 2010 ident: 2375_CR26 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2010.03.046 contributor: fullname: H Hikichi – volume: 3 start-page: 337 year: 2004 ident: 2375_CR59 publication-title: Genes Brain Behav doi: 10.1111/j.1601-183X.2004.00087.x contributor: fullname: QJ Yan – volume: 8 start-page: 1488 year: 1996 ident: 2375_CR37 publication-title: Eur J Neurosci doi: 10.1111/j.1460-9568.1996.tb01611.x contributor: fullname: R Lujan – volume: 38 start-page: 1493 year: 1999 ident: 2375_CR21 publication-title: Neuropharmacology doi: 10.1016/S0028-3908(99)00082-9 contributor: fullname: F Gasparini – volume: 40 start-page: 1 year: 2001 ident: 2375_CR58 publication-title: Neuropharmacology doi: 10.1016/S0028-3908(00)00113-1 contributor: fullname: K Walker – volume: 406 start-page: 403 year: 2000 ident: 2375_CR50 publication-title: Eur J Pharmacol doi: 10.1016/S0014-2999(00)00697-X contributor: fullname: WPJM Spooren – volume: 372 start-page: 237 year: 1994 ident: 2375_CR12 publication-title: Nature doi: 10.1038/372237a0 contributor: fullname: F Conquet – volume: 49 start-page: 1053 year: 2005 ident: 2375_CR60 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2005.06.004 contributor: fullname: QJ Yan – volume: 927 start-page: 8 year: 2002 ident: 2375_CR41 publication-title: Brain Res doi: 10.1016/S0006-8993(01)03309-1 contributor: fullname: DM Nielsen – volume: 18 start-page: 63 year: 2000 ident: 2375_CR48 publication-title: Handb Chem Neuroanat doi: 10.1016/S0924-8196(00)80044-5 contributor: fullname: R Shigemoto – volume: 29 start-page: 1971 year: 2004 ident: 2375_CR9 publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1300540 contributor: fullname: CS Busse |
| SSID | ssj0000484 ssj0068394 |
| Score | 2.3861945 |
| Snippet | Rationale
Studies in the
Fmr1
knockout (KO) mouse, a model of fragile X syndrome (FXS), suggest that excessive signaling through group I metabotropic glutamate... Studies in the Fmr1 knockout (KO) mouse, a model of fragile X syndrome (FXS), suggest that excessive signaling through group I metabotropic glutamate receptors... Rationale Studies in the Fmrl knockout (KO) mouse, a model of fragile X syndrome (FXS), suggest that excessive signaling through group I metabotropic glutamate... Rationale: Studies in the Fmr1 knockout (KO) mouse, a model of fragile X syndrome (FXS), suggest that excessive signaling through group I metabotropic... |
| SourceID | proquest gale crossref pubmed pascalfrancis springer |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 47 |
| SubjectTerms | Acoustic Stimulation - methods Amino acids Animal behavior Animal models Animals Antagonists Auditory stimuli Biological and medical sciences Biomedical and Life Sciences Biomedicine Data processing Disease Models, Animal Dose-Response Relationship, Drug Epilepsy fragile X mental retardation protein Fragile X Mental Retardation Protein - genetics Fragile X syndrome Fragile X Syndrome - genetics Fragile X Syndrome - psychology Glutamate Glutamic acid receptors (metabotropic) Male Medical sciences Mice Mice, Inbred C57BL Mice, Knockout Miscellaneous Motor skill learning Neurosciences Original Investigation Pathogenesis Pharmacology Pharmacology. Drug treatments Pharmacology/Toxicology Psychiatry Quinolines - pharmacology Receptor, Metabotropic Glutamate 5 Receptors, Metabotropic Glutamate - antagonists & inhibitors Receptors, Metabotropic Glutamate - physiology Reflex, Startle - drug effects Reflex, Startle - physiology Rodents Seizures Seizures (Medicine) |
| Title | Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome |
| URI | https://link.springer.com/article/10.1007/s00213-011-2375-4 https://www.ncbi.nlm.nih.gov/pubmed/21656124 https://www.proquest.com/docview/913176038 https://search.proquest.com/docview/926899019 |
| Volume | 219 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEA-2BRGKH1Xr2lrmQSpoV3azm03yeOiVU1QKVuhbyObjKOLecbt96H_vZD85rA_6uGw2IZPJzC8zO78Q8hp1JM1sKWNm0iLOrc1jUaIxZKmnsjR4QChDHHLxnX-7Eh_ngSaHjqGL6uf7ISPZGuqx1i14o_DrTxrTjLM43yF76HoY6vbebP558WWyv3koveweCvT_HRFzFsrImBgSm3f1uOWaegO9v9Y1Cst3t1zcBUP_SKG2nun80f_M6TF52ONQmHWK84Tcc9UBuf-1z7QfkNOLjtP69gwupxKt-gxO4WJiu759SjZt9Ao-wS_XoEI1m9X62sASFVojGHaAFtWt8WAPuIR6uQpEvTW0OXqo2zt4YGAKqOG6Ag0hFuGgvaEHEFEDCmWJpguuYGBXeEZ-nM8vPyzi_iKH2CBebGJqEutZ4ktuSqkF04UNPHI2SaxOmeXeJN4xaxxH8JJmhnuRSGFllvpCoBfPnpPdalW5FwQKKl1CvddoafIsEZJyrsMh0nqe-jKPyNthDdW64-tQIzNzK26F4lZB3AobvwmrrMJebjba6L4kAYcKrFhqliG-5JxREZHjrZa4B83W65MtPRmHxgObkNgoIkeD4qjeSNRKpgjeiiTDz2F8G3oO_71VDqWtJC1EyFzKiBx26jZ1HXiTEJ1F5N2gXFPXf53yy39qfUQeIECkXcjpmOw2mxv3iuzU9uak33W_ARkgI4Q |
| link.rule.ids | 315,782,786,27933,27934,41073,42142,48344,48347,48357,49649,49652,49662,52153 |
| linkProvider | Springer Nature |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6aBNpC6SN9uUnTOZQUmhj8lnRc2mx3aRIC3UJuQtZjyaHeZe0c8u878mOXpemhPRrJMh59Gn3SaD4BfCSMxKkpRZjruAgzY7KQl-QM89glotS0QCj9PuTkB7u85l_PvExOOuTCtKfdh5Bk66nXyW5-OvJnf-IwSVkeZjuwl4kiIyjvjaazb-ONA8587mX3UBAB6JSYU59HlvMhsnlfi1tzU--hnyxVTdZy3TUX9_HQP2Ko7dQ0fvZfP_UcnvZMFEcddF7AA1vtw8OLPta-D8dXnar13SnONkla9Ske49VG7_ruJaza_Suc4i_bEKSa1WJ5o3FOkFZEhy2ST7VLWtojdaKaL7xUb41tlB7r9hYeHLQCarypUKHfjbDY3tGDxKmRrDIn54XXOOgrvIKf47PZl0nYX-UQamKMTZjoyLg8ciXTpVA8V4XxSnImioyKc8OcjpzNjbaM6EucauZ4JLgRaewKTvN4-hp2q0Vl3wIWibBR4pwiX5OlERcJY8ovI41jsSuzAD4PnSiXnWKHXGszt-aWZG7pzS2p8iffzdKP5maltOqTEuhTXhdLjlJimIzlCQ_gcKsmjUK9VXy0BZT1p2nJxgVVCuBgQI7s3UQtRUz0rYhSeh3Xpb5lf_KtsmRtKZKC-9ilCOBNh7dN0145ifhZACcDuDZN__WX3_1T7Q_waDK7OJfn08vvB_CY6GLSbUAdwm6zurXvYac2t0f9EPwNi50ndA |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxEB7RVqqQUIHyaGgpc0BFgq66b9snFNFEKZQqEkXqzfL6EfXAJspuD_33jPeRKKIcEMdoHa92_Hn8jcfzGeA9YSRKTCGCTEd5kBqTBrwgZ5hFLhaFpgCh8PuQkx_s6oafj7xMzue-FqY57d6nJNuaBq_SVNZnC-POVoVvfmny54CiIE5YFqRbsJNSIENA3xmOvk4u18449XWY7Y-cyECrypz4mrKM91nOh3rcWKc6b_1koSqynGuvvHiIk_6RT22WqfHT__7AZ7DXMVQctpB6Do9suQ-737sc_D6cTFu16_tTvF4Xb1WneILTtQ72_QtYNvtaeIG_bE1Qq5fzxa3GGUFdEU22SL7WLijkRxpcNZt7Cd8Km-w9Vs3tPNhrCFR4W6JCv0thsbm7B4lrI1loRk4Nb7DXXXgJP8ej6y-ToLviIdDEJOsg1qFxWegKpguheKZy4xXmTBgaFWWGOR06mxltGdGaKNHM8VBwI5LI5ZzW9-QVbJfz0h4A5rGwYeycIh-UJiEXMWPKh5fGscgV6QA-9gMqF62Sh1xpNjfmlmRu6c0tqfEHP-TSz_J6qbTqihXoVV4vSw4TYp6MZTEfwNFGS5qdeuPx8QZoVq-mUI4LajSAwx5FsnMflRQR0bo8TOjvuHrqe_Yn4kpL1pYizrnPaYoBvG6xt-7aKyoRbxvApx5o667_-slv_qn1O9idno_l5cXVt0N4TCwybveljmC7Xt7Zt7BVmbvjbjb-BgPjMDc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Group+I+metabotropic+glutamate+receptor+antagonists+alter+select+behaviors+in+a+mouse+model+for+fragile+X+syndrome&rft.jtitle=Psychopharmacology&rft.au=Thomas%2C+Alexia+M.&rft.au=Bui%2C+Nghiem&rft.au=Perkins%2C+Jennifer+R.&rft.au=Yuva-Paylor%2C+Lisa+A.&rft.date=2012-01-01&rft.pub=Springer-Verlag&rft.issn=0033-3158&rft.eissn=1432-2072&rft.volume=219&rft.issue=1&rft.spage=47&rft.epage=58&rft_id=info:doi/10.1007%2Fs00213-011-2375-4&rft.externalDocID=10_1007_s00213_011_2375_4 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon |